HRP20120510T1 - Derivati beta amino kiseline za liječenje dijabetesa - Google Patents
Derivati beta amino kiseline za liječenje dijabetesa Download PDFInfo
- Publication number
- HRP20120510T1 HRP20120510T1 HRP20120510AT HRP20120510T HRP20120510T1 HR P20120510 T1 HRP20120510 T1 HR P20120510T1 HR P20120510A T HRP20120510A T HR P20120510AT HR P20120510 T HRP20120510 T HR P20120510T HR P20120510 T1 HRP20120510 T1 HR P20120510T1
- Authority
- HR
- Croatia
- Prior art keywords
- isoindol
- propionamide
- dihydro
- oxo
- phenyl
- Prior art date
Links
- 150000001576 beta-amino acids Chemical class 0.000 title 1
- 206010012601 diabetes mellitus Diseases 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims abstract 14
- 150000003839 salts Chemical class 0.000 claims 10
- 239000000203 mixture Substances 0.000 claims 8
- 239000003814 drug Substances 0.000 claims 6
- 229940079593 drug Drugs 0.000 claims 5
- -1 benzo[1,3]dioxolyl Chemical group 0.000 claims 4
- APRATTNDLORJFG-UHFFFAOYSA-N 3-(3,4-dimethoxyphenyl)-3-(3-oxo-1h-isoindol-2-yl)-n-pyridin-2-ylpropanamide Chemical compound C1=C(OC)C(OC)=CC=C1C(N1C(C2=CC=CC=C2C1)=O)CC(=O)NC1=CC=CC=N1 APRATTNDLORJFG-UHFFFAOYSA-N 0.000 claims 2
- RMUULXHVYNHZBF-UHFFFAOYSA-N 3-(3,4-dimethoxyphenyl)-n-(5-methylpyridin-2-yl)-3-(3-oxo-1h-isoindol-2-yl)propanamide Chemical compound C1=C(OC)C(OC)=CC=C1C(N1C(C2=CC=CC=C2C1)=O)CC(=O)NC1=CC=C(C)C=N1 RMUULXHVYNHZBF-UHFFFAOYSA-N 0.000 claims 2
- OEJXYAKMUUFPMI-UHFFFAOYSA-N 3-(3,4-dimethoxyphenyl)-n-(6-methylpyridin-2-yl)-3-(3-oxo-1h-isoindol-2-yl)propanamide Chemical compound C1=C(OC)C(OC)=CC=C1C(N1C(C2=CC=CC=C2C1)=O)CC(=O)NC1=CC=CC(C)=N1 OEJXYAKMUUFPMI-UHFFFAOYSA-N 0.000 claims 2
- SBVFNYIOAWKDSB-UHFFFAOYSA-N 3-(3-oxo-1h-isoindol-2-yl)-n-(1,3-thiazol-2-yl)-3-(3,4,5-trimethoxyphenyl)propanamide Chemical compound COC1=C(OC)C(OC)=CC(C(CC(=O)NC=2SC=CN=2)N2C(C3=CC=CC=C3C2)=O)=C1 SBVFNYIOAWKDSB-UHFFFAOYSA-N 0.000 claims 2
- DZIWVUSUJHPTIN-UHFFFAOYSA-N 3-(3-oxo-1h-isoindol-2-yl)-n-pyridin-2-yl-3-(3,4,5-trimethoxyphenyl)propanamide Chemical compound COC1=C(OC)C(OC)=CC(C(CC(=O)NC=2N=CC=CC=2)N2C(C3=CC=CC=C3C2)=O)=C1 DZIWVUSUJHPTIN-UHFFFAOYSA-N 0.000 claims 2
- IPSFXCHUNUDSKS-UHFFFAOYSA-N 3-(3-oxo-1h-isoindol-2-yl)-n-pyridin-2-yl-3-thiophen-2-ylpropanamide Chemical compound C=1C=CC=NC=1NC(=O)CC(N1C(C2=CC=CC=C2C1)=O)C1=CC=CS1 IPSFXCHUNUDSKS-UHFFFAOYSA-N 0.000 claims 2
- XRUMTIMHZVQDQA-UHFFFAOYSA-N 3-(4-methoxyphenyl)-3-(3-oxo-1h-isoindol-2-yl)-n-pyridin-2-ylpropanamide Chemical compound C1=CC(OC)=CC=C1C(N1C(C2=CC=CC=C2C1)=O)CC(=O)NC1=CC=CC=N1 XRUMTIMHZVQDQA-UHFFFAOYSA-N 0.000 claims 2
- ITRSBXAOJQVEOW-UHFFFAOYSA-N 3-(4-methoxyphenyl)-n-(4-methylpyridin-2-yl)-3-(3-oxo-1h-isoindol-2-yl)propanamide Chemical compound C1=CC(OC)=CC=C1C(N1C(C2=CC=CC=C2C1)=O)CC(=O)NC1=CC(C)=CC=N1 ITRSBXAOJQVEOW-UHFFFAOYSA-N 0.000 claims 2
- QXIJITNYCCMZDI-UHFFFAOYSA-N 3-(4-methoxyphenyl)-n-(5-methylpyridin-2-yl)-3-(3-oxo-1h-isoindol-2-yl)propanamide Chemical compound C1=CC(OC)=CC=C1C(N1C(C2=CC=CC=C2C1)=O)CC(=O)NC1=CC=C(C)C=N1 QXIJITNYCCMZDI-UHFFFAOYSA-N 0.000 claims 2
- PMYSKYMHOVWMAB-UHFFFAOYSA-N 3-(4-methoxyphenyl)-n-(6-methylpyridin-2-yl)-3-(3-oxo-1h-isoindol-2-yl)propanamide Chemical compound C1=CC(OC)=CC=C1C(N1C(C2=CC=CC=C2C1)=O)CC(=O)NC1=CC=CC(C)=N1 PMYSKYMHOVWMAB-UHFFFAOYSA-N 0.000 claims 2
- 239000004480 active ingredient Substances 0.000 claims 2
- 239000002671 adjuvant Substances 0.000 claims 2
- 125000000217 alkyl group Chemical group 0.000 claims 2
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 claims 2
- 125000002619 bicyclic group Chemical group 0.000 claims 2
- 125000004432 carbon atom Chemical group C* 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 125000002541 furyl group Chemical group 0.000 claims 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 2
- 125000002883 imidazolyl group Chemical group 0.000 claims 2
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 claims 2
- 125000001041 indolyl group Chemical group 0.000 claims 2
- 125000002950 monocyclic group Chemical group 0.000 claims 2
- STOZBSVDJISXRI-UHFFFAOYSA-N n-(4-methyl-1,3-thiazol-2-yl)-3-(3-oxo-1h-isoindol-2-yl)-3-(3,4,5-trimethoxyphenyl)propanamide Chemical compound COC1=C(OC)C(OC)=CC(C(CC(=O)NC=2SC=C(C)N=2)N2C(C3=CC=CC=C3C2)=O)=C1 STOZBSVDJISXRI-UHFFFAOYSA-N 0.000 claims 2
- IBRUVOZFXCYUPN-UHFFFAOYSA-N n-(5-bromopyridin-2-yl)-3-(3,4-dimethoxyphenyl)-3-(3-oxo-1h-isoindol-2-yl)propanamide Chemical compound C1=C(OC)C(OC)=CC=C1C(N1C(C2=CC=CC=C2C1)=O)CC(=O)NC1=CC=C(Br)C=N1 IBRUVOZFXCYUPN-UHFFFAOYSA-N 0.000 claims 2
- BPWWAPBGDABIHH-UHFFFAOYSA-N n-(5-bromopyridin-2-yl)-3-(3-oxo-1h-isoindol-2-yl)-3-(3,4,5-trimethoxyphenyl)propanamide Chemical compound COC1=C(OC)C(OC)=CC(C(CC(=O)NC=2N=CC(Br)=CC=2)N2C(C3=CC=CC=C3C2)=O)=C1 BPWWAPBGDABIHH-UHFFFAOYSA-N 0.000 claims 2
- KTMPTXPTUBHTDC-UHFFFAOYSA-N n-(5-bromopyridin-2-yl)-3-(4-methylphenyl)-3-(3-oxo-1h-isoindol-2-yl)propanamide Chemical compound C1=CC(C)=CC=C1C(N1C(C2=CC=CC=C2C1)=O)CC(=O)NC1=CC=C(Br)C=N1 KTMPTXPTUBHTDC-UHFFFAOYSA-N 0.000 claims 2
- KMDDPCCZBHXPDA-UHFFFAOYSA-N n-(5-chloropyridin-2-yl)-3-(3,4-dimethoxyphenyl)-3-(3-oxo-1h-isoindol-2-yl)propanamide Chemical compound C1=C(OC)C(OC)=CC=C1C(N1C(C2=CC=CC=C2C1)=O)CC(=O)NC1=CC=C(Cl)C=N1 KMDDPCCZBHXPDA-UHFFFAOYSA-N 0.000 claims 2
- PQFKHILISYWWMV-UHFFFAOYSA-N n-(5-chloropyridin-2-yl)-3-(3-oxo-1h-isoindol-2-yl)-3-(3,4,5-trimethoxyphenyl)propanamide Chemical compound COC1=C(OC)C(OC)=CC(C(CC(=O)NC=2N=CC(Cl)=CC=2)N2C(C3=CC=CC=C3C2)=O)=C1 PQFKHILISYWWMV-UHFFFAOYSA-N 0.000 claims 2
- HQANKEHGKYKJBR-UHFFFAOYSA-N n-(5-chloropyridin-2-yl)-3-(4-fluorophenyl)-3-(3-oxo-1h-isoindol-2-yl)propanamide Chemical compound C1=CC(F)=CC=C1C(N1C(C2=CC=CC=C2C1)=O)CC(=O)NC1=CC=C(Cl)C=N1 HQANKEHGKYKJBR-UHFFFAOYSA-N 0.000 claims 2
- CYEJTXYXGQXFTD-UHFFFAOYSA-N n-(5-methylpyridin-2-yl)-3-(3-oxo-1h-isoindol-2-yl)-3-(3,4,5-trimethoxyphenyl)propanamide Chemical compound COC1=C(OC)C(OC)=CC(C(CC(=O)NC=2N=CC(C)=CC=2)N2C(C3=CC=CC=C3C2)=O)=C1 CYEJTXYXGQXFTD-UHFFFAOYSA-N 0.000 claims 2
- BXKIVTINPIYLNI-UHFFFAOYSA-N n-(6-methylpyridin-2-yl)-3-(3-oxo-1h-isoindol-2-yl)-3-(3,4,5-trimethoxyphenyl)propanamide Chemical compound COC1=C(OC)C(OC)=CC(C(CC(=O)NC=2N=C(C)C=CC=2)N2C(C3=CC=CC=C3C2)=O)=C1 BXKIVTINPIYLNI-UHFFFAOYSA-N 0.000 claims 2
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 2
- 125000002971 oxazolyl group Chemical group 0.000 claims 2
- 125000004430 oxygen atom Chemical group O* 0.000 claims 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 2
- 125000003373 pyrazinyl group Chemical group 0.000 claims 2
- 125000003226 pyrazolyl group Chemical group 0.000 claims 2
- 125000002098 pyridazinyl group Chemical group 0.000 claims 2
- 125000004076 pyridyl group Chemical group 0.000 claims 2
- 125000000714 pyrimidinyl group Chemical group 0.000 claims 2
- 125000000168 pyrrolyl group Chemical group 0.000 claims 2
- 125000004434 sulfur atom Chemical group 0.000 claims 2
- 125000003831 tetrazolyl group Chemical group 0.000 claims 2
- 125000000335 thiazolyl group Chemical group 0.000 claims 2
- 125000001544 thienyl group Chemical group 0.000 claims 2
- 125000001425 triazolyl group Chemical group 0.000 claims 2
- 208000008589 Obesity Diseases 0.000 claims 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 1
- 125000000842 isoxazolyl group Chemical group 0.000 claims 1
- 208000017169 kidney disease Diseases 0.000 claims 1
- 229940126601 medicinal product Drugs 0.000 claims 1
- 201000001119 neuropathy Diseases 0.000 claims 1
- 230000007823 neuropathy Effects 0.000 claims 1
- 235000020824 obesity Nutrition 0.000 claims 1
- 208000033808 peripheral neuropathy Diseases 0.000 claims 1
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 claims 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP08001305 | 2008-01-24 | ||
| PCT/EP2008/011099 WO2009092432A1 (en) | 2008-01-24 | 2008-12-23 | Beta-amino acid derivatives for treatment of diabetes |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20120510T1 true HRP20120510T1 (hr) | 2012-07-31 |
Family
ID=40386192
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20120510AT HRP20120510T1 (hr) | 2008-01-24 | 2012-06-19 | Derivati beta amino kiseline za liječenje dijabetesa |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US8431602B2 (ko) |
| EP (1) | EP2231640B1 (ko) |
| JP (1) | JP5623914B2 (ko) |
| KR (1) | KR20100110367A (ko) |
| CN (1) | CN101925596B (ko) |
| AR (1) | AR070232A1 (ko) |
| AU (1) | AU2008348817B2 (ko) |
| BR (1) | BRPI0821827A2 (ko) |
| CA (1) | CA2712998A1 (ko) |
| CY (1) | CY1112919T1 (ko) |
| DK (1) | DK2231640T3 (ko) |
| EA (1) | EA017775B1 (ko) |
| ES (1) | ES2388475T3 (ko) |
| HR (1) | HRP20120510T1 (ko) |
| IL (1) | IL206904A0 (ko) |
| MX (1) | MX2010007926A (ko) |
| PL (1) | PL2231640T3 (ko) |
| PT (1) | PT2231640E (ko) |
| SI (1) | SI2231640T1 (ko) |
| WO (1) | WO2009092432A1 (ko) |
| ZA (1) | ZA201006002B (ko) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2011107494A1 (de) | 2010-03-03 | 2011-09-09 | Sanofi | Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung |
| US8530413B2 (en) | 2010-06-21 | 2013-09-10 | Sanofi | Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments |
| TW201215387A (en) | 2010-07-05 | 2012-04-16 | Sanofi Aventis | Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament |
| TW201215388A (en) | 2010-07-05 | 2012-04-16 | Sanofi Sa | (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments |
| TW201221505A (en) | 2010-07-05 | 2012-06-01 | Sanofi Sa | Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament |
| WO2013037390A1 (en) | 2011-09-12 | 2013-03-21 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
| EP2760862B1 (en) | 2011-09-27 | 2015-10-21 | Sanofi | 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
| CA3001799A1 (en) | 2015-10-21 | 2017-04-27 | Otsuka Pharmaceutical Co., Ltd. | Benzolactam compounds as protein kinase inhibitors |
| GB201706327D0 (en) | 2017-04-20 | 2017-06-07 | Otsuka Pharma Co Ltd | A pharmaceutical compound |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5698579A (en) * | 1993-07-02 | 1997-12-16 | Celgene Corporation | Cyclic amides |
| US6482951B2 (en) * | 2000-12-13 | 2002-11-19 | Hoffmann-La Roche Inc. | Isoindolin-1-one glucokinase activators |
| ZA200503024B (en) | 2002-10-15 | 2006-11-29 | Celgene Corp | Selective cytokine inhibitory drugs for treating myelodysplastic syndrome |
| CN1802353A (zh) * | 2002-12-30 | 2006-07-12 | 细胞基因公司 | 氟烷氧基取代的1,3－二氢－异吲哚化合物及其药物用途 |
| AU2005302523A1 (en) * | 2004-10-28 | 2006-05-11 | Celgene Corporation | Methods and compositions using PDE4 modulators for treatment and management of central nervous system injury |
| US8008332B2 (en) * | 2006-05-31 | 2011-08-30 | Takeda San Diego, Inc. | Substituted indazoles as glucokinase activators |
-
2008
- 2008-12-23 EP EP08871581A patent/EP2231640B1/en active Active
- 2008-12-23 WO PCT/EP2008/011099 patent/WO2009092432A1/en active Application Filing
- 2008-12-23 PT PT08871581T patent/PT2231640E/pt unknown
- 2008-12-23 CA CA2712998A patent/CA2712998A1/en not_active Abandoned
- 2008-12-23 ES ES08871581T patent/ES2388475T3/es active Active
- 2008-12-23 SI SI200830736T patent/SI2231640T1/sl unknown
- 2008-12-23 US US12/864,348 patent/US8431602B2/en active Active
- 2008-12-23 MX MX2010007926A patent/MX2010007926A/es active IP Right Grant
- 2008-12-23 PL PL08871581T patent/PL2231640T3/pl unknown
- 2008-12-23 CN CN200880125427.7A patent/CN101925596B/zh not_active Expired - Fee Related
- 2008-12-23 EA EA201001174A patent/EA017775B1/ru not_active IP Right Cessation
- 2008-12-23 DK DK08871581.8T patent/DK2231640T3/da active
- 2008-12-23 BR BRPI0821827-7A patent/BRPI0821827A2/pt not_active IP Right Cessation
- 2008-12-23 KR KR1020107018265A patent/KR20100110367A/ko not_active Application Discontinuation
- 2008-12-23 JP JP2010543387A patent/JP5623914B2/ja active Active
- 2008-12-23 AU AU2008348817A patent/AU2008348817B2/en not_active Ceased
-
2009
- 2009-01-23 AR ARP090100201A patent/AR070232A1/es unknown
-
2010
- 2010-07-08 IL IL206904A patent/IL206904A0/en unknown
- 2010-08-23 ZA ZA2010/06002A patent/ZA201006002B/en unknown
-
2012
- 2012-06-19 HR HRP20120510AT patent/HRP20120510T1/hr unknown
- 2012-07-24 CY CY20121100656T patent/CY1112919T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EA017775B1 (ru) | 2013-03-29 |
| KR20100110367A (ko) | 2010-10-12 |
| AU2008348817A1 (en) | 2009-07-30 |
| JP2011510029A (ja) | 2011-03-31 |
| PL2231640T3 (pl) | 2012-09-28 |
| WO2009092432A1 (en) | 2009-07-30 |
| CY1112919T1 (el) | 2016-04-13 |
| CN101925596B (zh) | 2014-05-28 |
| JP5623914B2 (ja) | 2014-11-12 |
| EP2231640B1 (en) | 2012-06-06 |
| PT2231640E (pt) | 2012-08-23 |
| BRPI0821827A2 (pt) | 2015-06-16 |
| US8431602B2 (en) | 2013-04-30 |
| SI2231640T1 (sl) | 2012-09-28 |
| IL206904A0 (en) | 2010-12-30 |
| US20100331346A1 (en) | 2010-12-30 |
| MX2010007926A (es) | 2010-08-09 |
| ES2388475T3 (es) | 2012-10-15 |
| EP2231640A1 (en) | 2010-09-29 |
| CN101925596A (zh) | 2010-12-22 |
| AU2008348817B2 (en) | 2011-12-15 |
| ZA201006002B (en) | 2011-04-28 |
| CA2712998A1 (en) | 2009-07-30 |
| DK2231640T3 (da) | 2012-07-16 |
| AR070232A1 (es) | 2010-03-25 |
| EA201001174A1 (ru) | 2011-02-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20120510T1 (hr) | Derivati beta amino kiseline za liječenje dijabetesa | |
| KR101464060B1 (ko) | 피라졸-4-일-헤테로사이클릴-카복사마이드 화합물 및 사용 방법 | |
| ES2312051T3 (es) | Compuestos que ejercen efecto sobre la glucoquinasa. | |
| ES2691068T3 (es) | Compuestos de indol e indazol como inhibidores de la necrosis celular | |
| KR102398473B1 (ko) | Tam 패밀리 키나제 억제제로서의 아미노피리딘 유도체 | |
| JP2011510029A5 (ko) | ||
| WO2013006408A1 (en) | Compounds and methods | |
| JP2016135778A (ja) | シアノトリアゾール化合物の医薬用途 | |
| EP2906553A1 (en) | Orexin receptor antagonists which are [ortho bi (hetero )aryl]-[2-(meta bi (hetero)aryl)-pyrrolidin-1-yl]-methanone derivatives | |
| KR101584826B1 (ko) | 스테아로일-ＣｏＡ 데새투라제의 헤테로시클릭 억제제 | |
| CA2684105A1 (en) | Pyridine derivatives | |
| JP2016525069A (ja) | シアノトリアゾール化合物 | |
| RU2013143028A (ru) | Тиазолилфенилбензолсульфонамидопроизводные в качестве ингибиторов киназ | |
| RU2001131104A (ru) | Новые производные бензимидазола и содержащие эти соединения фармацевтические композиции | |
| RU2015138964A (ru) | Полициклические модуляторы рецептора эстрогена и их применения | |
| CA2478229A1 (en) | Pyridinoylpiperidines as 5-ht1f agonists | |
| AU2006275403A1 (en) | 2-aminoaryl pyridines as protein kinases inhibitors | |
| BRPI0720452A2 (pt) | Compostos orgânicos | |
| RU2015101102A (ru) | Гетероароматическое метильное производное циклического амина | |
| HRP20230789T1 (hr) | Derivati benzhidroksamske kiseline kao selektivni inhibitori hdac6 | |
| RU2012134306A (ru) | Азотосодержащие производные гетероарилов | |
| HRP20120979T1 (hr) | Derivati piridazinona | |
| BR112016017317B1 (pt) | Composto, e, uso de um composto | |
| JP2018527325A5 (ko) | ||
| JP2014516070A5 (ko) |